tbuckley/cabot-search huggingface dataset:
Planning Adjuvant Trials When Regimens Effective for Patients With Advanced Disease Don’t Work in the Adjuvant Setting—Paradigms Lost
Authors: Bhupinder Mann, James Zwiebel
Journal: JAMA Oncology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Is Elevated Serum IL-10 in B-CLL Associated with IL-10 Promoter Polymorphisms?.
Authors: Charles C. Chu, Stephanie T. Reese, Leslie O. Goodwin, Dorothy Guzowski, Alamelu Chandrasekaran, Craig Gawel, Wentian Li, Peter K. Gregersen, Xiao J. Yan, Barbara Sherry, Michael Centola, Steven L. Allen, Kanti R. Rai, Nicholas Chiorazzi
Journal: Blood (2005)
Repetitive High-Dose Therapy with Dose Escalated CHOP + Etoposide Followed by Autologous Stem Cell Transplantation (Mega-CHOEP) in Younger Patients with Primary Diagnosis of Aggressive NHL and Elevated LDH at Diagnosis: Final Analysis.
Authors: Norbert Schmitz, Marita Kloess, Andreas Engert, Wolfgang E. Berdel, Bernd Metzner, Lorenz Truemper, Marcus Loeffler, Michael Pfreundschuh, Bertram Glass
Journal: Blood (2004)
Abstract P1-02-13: Differential expression of exosomal miRNAs between breast cancer patients with recurrence and no-recurrence
Authors: A Sueta, Y Yamamoto, M Tomiguchi, T Takeshita, M Ibusuki, H Iwase
Journal: Cancer Research (2017)

Abstract Background In recent years, there has been a concerted effort to identify biomarkers derived from body fluid in various cancers. Exosomal microRNA (miRNA) has been used as one of useful diagnostic or prognostic biomarkers. We aimed to investigate the prognostic role of the exosomal miRNAs in serum samples derived from patients with primary breast cancer. Additionally, we evaluated whether the exosomal miRNA in serum reflect the origin of primary tumor by means of comparing their expression levels between in serum and tumors. Patients and Methods Exosomes in serum sample (500uL) were extracted using ExoQuick (System Biosciences) and miRNAs were isolated using SeraMirTM Exosome RNA Amplification Kit (SBI). We compared the miRNA profile derived from exosome between the patients with breast cancer with recurrence (n=16) and without recurrence (n=16) by miRNA PCR array. Further, we examined the expression of miRNA derived from tumor tissues in the patients with breast cancer recurrence (n=35) and without recurrence (n=39) by qRT-PCR. All samples were collected before treatment and surgery. Results Of the 384 miRNAs, 11 miRNAs were significantly expressed; three miRNAs (miR-338-3p, miR-340-5p, and miR-124-3p) were significantly up-regulated and eight (miR-29b-3p, miR-20b-5p, miR-17-5p, miR-130a-3p, miR-18a-5p, miR-195-5p, miR-486-5p, and miR-93a-5p) were significantly down-regulated in the patients with recurrence compared to those without recurrence. Next, we evaluated expression of the above miRNAs in tumor tissues. The patients with recurrence have higher levels of miR-340 at their primary site as well as in the serum. On the contrary, miR-195-5p, miR-17-5p, miR-93-5p, and miR-130a-3p derived from tumor tissues that were down-regulated in the patients with recurrence in serum, were highly expressed in the patients with recurrence than those with no-recurrence. In logistic regression analysis, tumor size, miR-340-5p, miR-17-5p, miR-130a-3p, and miR-93-5p were significantly associated with breast cancer recurrence (each P &amp;lt; 0.05). Conclusions Several exosomal miRNAs at diagnosis may be useful biomarker to predict the breast cancer recurrence. Moreover, we showed the different expression pattern of miRNAs between tumor tissues and serum. These findings may suggest selective mechanism of release of exosomal miRNA by cancer cells to regulate their progression. Further studies to confirm our results are needed. Citation Format: Sueta A, Yamamoto Y, Tomiguchi M, Takeshita T, Ibusuki M, Iwase H. Differential expression of exosomal miRNAs between breast cancer patients with recurrence and no-recurrence [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-02-13.
Crizanlizumab Prevents Sickle Cell Pain Crises
Authors: Anita Slomski
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes
Authors: Chen Wang, Sebastian M. Armasu, Kimberly R. Kalli, Matthew J. Maurer, Ethan P. Heinzen, Gary L. Keeney, William A. Cliby, Ann L. Oberg, Scott H. Kaufmann, Ellen L. Goode
Journal: Clinical Cancer Research (2017)

Purpose: Here we assess whether molecular subtyping identifies biological features of tumors that correlate with survival and surgical outcomes of high-grade serous ovarian cancer (HGSOC).Experimental Design: Consensus clustering of pooled mRNA expression data from over 2,000 HGSOC cases was used to define molecular subtypes of HGSOCs. This de novo classification scheme was then applied to 381 Mayo Clinic HGSOC patients with detailed survival and surgical outcome information.Results: Five molecular subtypes of HGSOC were identified. In the pooled dataset, three subtypes were largely concordant with prior studies describing proliferative, mesenchymal, and immunoreactive tumors (concordance > 70%), and the group of tumors previously described as differentiated type was segregated into two new types, one of which (anti-mesenchymal) had downregulation of genes that were typically upregulated in the mesenchymal subtype. Molecular subtypes were significantly associated with overall survival (P < 0.001) and with rate of optimal surgical debulking (≤1 cm, P = 1.9E-4) in the pooled dataset. Among stage III-C or IV Mayo Clinic patients, molecular subtypes were also significantly associated with overall survival (P = 0.001), as well as rate of complete surgical debulking (no residual disease; 16% in mesenchymal tumors compared with >28% in other subtypes; P = 0.02).Conclusions: HGSOC tumors may be categorized into five molecular subtypes that associate with overall survival and the extent of residual disease following debulking surgery. Because mesenchymal tumors may have features that were associated with less favorable surgical outcome, molecular subtyping may have future utility in guiding neoadjuvant treatment decisions for women with HGSOC. Clin Cancer Res; 23(15); 4077-85. ©2017 AACR.
Abstract P1-11-14: Breast conserving therapy and mastectomy revisited: overall and breast cancer-specific survival and the influence of age, stage, receptor status and comorbidities in 143,376 patients
Authors: M Lagendijk, MC van Maaren, S Saadatmand, LJA Strobbe, P Poortmans, LB Koppert, MMA Tilanus-Linthorst, S Siesling
Journal: Cancer Research (2017)

Abstract This abstract was withdrawn by the authors.
The Pre-B Cell Receptor Suppresses Leukemogenesis by Censoring MYC Expression.
Authors: Rahul Nahar, Daniel Trageser, Lars Klemm, Cihangir Duy, Peter van Essen, Yong-mi Kim, Nora Heisterkamp, Giovanni Martinelli, Wolf-Karsten Hofmann, Hans-Martin Jack, Hassan Jumaa, Markus Muschen
Journal: Blood (2008)
Use of 2HG Levels in the Serum, Urine, or Bone Marrow to Predict IDH Mutations in Adults with Acute Myeloid Leukemia
Authors: Andrew M. Brunner, Donna S Neuberg, Seth A. Wander, Hossein Sadrzadeh, Karen K. Ballen, Philip C. Amrein, Gabriela S. Hobbs, Yi-Bin Chen, Ashley M. Perry, Christelle Joseph, Meghan E. Burke, Aura Y Ramos, Regina Silver, Ilene Galinsky, Sophia Adamia, Darrell Borger, Anthony J Iafrate, Richard M. Stone, Amir T. Fathi
Journal: Blood (2015)
Abstract B45: Huntsman Cancer Institute Preclinical Research Resource (PRR) Core
Authors: Brittni Smith, Oksana Kavetska, Guoying Wang, David Henry Lum
Journal: Clinical Cancer Research (2016)

Abstract Accumulating evidence from recent genomics data has reinforced the view that tumors can display exceptional heterogeneity between patients, between tumors from the same patient and even within a single tumor. These findings, together with decades of clinical experience with varied drug responses, strongly suggest that personalized approaches to assess cancer risk and treatment will be essential to reduce mortality. New experimental models of human tumor initiation, progression, metastasis, and therapeutic response/resistance are critical to improve cancer treatments. Current models often fail to predict the efficacy of drugs in the clinical setting. This disconnect leads to disappointing clinical trial results that do not considerably improve patient survival, to failure of the FDA to approve new therapies, and to the loss of time and money. The ideal cancer model(s) would: 1) replicate the spectrum of tumor pathologies and subtypes, 2) reproduce genetic and epigenetic alterations found in human tumors, 3) grow in the correct developmental and anatomic context, 4) have an appropriate tumor microenvironment and an intact immune system, and 5) exhibit patterns of metastasis observed in patients. Dr. Alana Welm (HCI) has established a collection of patient-derived orthotopic breast xenografts by implanting patient tumor tissue into mice. Significant evidence demonstrates that patient-derived xenografts (PDX) recapitulate the genomic and phenotypic features of their corresponding patient tumors, and that tumor graft growth and metastasis mirrors clinical outcome in the corresponding patients. We believe that PDXs may provide a remarkable opportunity to predict the best therapy regimens for individuals, a concept termed “personalized” or “precision” medicine. The Preclinical Research Resource (PRR) Core will provide high-quality services for basic and translational cancer research, drug discovery and personalized cancer therapy. The mission of the core will be to: generate the most current and sophisticated patient-derived in vivo cancer models; bridge the gap between basic scientists and clinicians to facilitate seamless bench-to-bedside research; and improve pre-clinical drug efficacy evaluation and examine personalized chemotherapy with patient-derived xenografts. Citation Format: Brittni Smith, Oksana Kavetska, Guoying Wang, David Henry Lum{Authors}. Huntsman Cancer Institute Preclinical Research Resource (PRR) Core. [abstract]. In: Proceedings of the AACR Special Conference: Patient-Derived Cancer Models: Present and Future Applications from Basic Science to the Clinic; Feb 11-14, 2016; New Orleans, LA. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(16_Suppl):Abstract nr B45.
Abstract IA09: Expression profiling of colorectal cancer PDX models for disease stratification and tumor-stroma interaction analysis
Authors: Enzo Medico
Journal: Clinical Cancer Research (2016)

Abstract Tumor-stroma interactions have long been implicated in neoplastic aggressiveness and resistance to treatment. In PDX models, after engraftment, the stromal components are contributed by the mouse host. As a consequence, transcripts expressed by cancer cells can be distinguished from stromal transcripts by their species of origin. We therefore exploited species-specific expression profiling of colorectal cancer (CRC) PDXs to evaluate the involvement of stromal components in recently defined CRC transcriptional subtypes. We found that stroma-derived transcripts profoundly affect the overall tumor transcriptome, and that a previously defined poor prognosis subtype is actually endowed with abundant stroma. To stratify CRC based on cancer cell-intrinsic transcriptional features, we performed class discovery on a human-specific gene expression dataset of 515 CRC PDXs, and identified five CRC intrinsic subtypes (CRIS). CRIS classification successfully categorized independent sets of primary and metastatic CRC tumors, with limited overlap on existing transcriptional classes and unprecedented predictive and prognostic performances. In a complementary approach, we focused on stroma-specific transcripts to define expression signatures reflecting the abundance in human CRC samples of fibroblasts, leukocytes and endothelial cells. Stromal scores were found to correlate with poor CRC prognosis and resistance of rectal cancer to preoperative radiotherapy, highlighting the microenvironment as a variable and dynamic component of CRC, with diagnostic and therapeutic potential. Citation Format: Enzo Medico. Expression profiling of colorectal cancer PDX models for disease stratification and tumor-stroma interaction analysis. [abstract]. In: Proceedings of the AACR Special Conference: Patient-Derived Cancer Models: Present and Future Applications from Basic Science to the Clinic; Feb 11-14, 2016; New Orleans, LA. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(16_Suppl):Abstract nr IA09.
Abstract OT3-04-04: 21-gene recurrence score® in patients with primary metastatic ER+ HER2- breast cancer
Authors: J Barinoff, L Anastasiadou, C Brandi, A Junker-Stein, J Silbermann, M Langenfeld, C Fortmann, M Thill
Journal: Cancer Research (2017)

Abstract Background and Purpose Results from the 21-gene Recurrence Score (RS) are prognostic and predictive for recurrence in early breast cancer independent of clinical-pathological parameters. Prognostic information and distribution of RS in primary metastatic breast cancer (PMBC) was reported in a previous study by King et al but remains ultimately unclear in ER+ HER2- patients. We hypothesize that there is a prognostic correlation between RS and TTP/OS in PMBCindependent of clinical-pathological parameters, and the objective of the study is to evaluate the test for that cohort. Patients and Trial Design Between 2004 and 2014, 150 patients with first diagnosis of ER+/HER2- PMBC were enrolled in a multicenter, prospectively collected database. Pretreatment breast tumor samples will be analyzed by using 21-gene RS. Minimum follow-up will be 24 months. Methods and Statistical Analysis Patient characteristics, time to first progression (TTP), overall survival (OS) and treatment modalities will be described. The association between RS risk groups and both TTP and OS will be assessed by Kaplan-Meier estimates and compared with the log-rank test. Multivariate Cox regression models will be utilized to adjust for covariates. Additionally, assessing correlation of RS results using RS cut offs of 18 and 30 and additionally of 11 and 25 as well as analysis of quantitative ER from Oncotype DX assay for patients treated first-line with endocrine therapy are planned. First results are expected to be presented in 2017. Contact information for people with a specific interest in the trial: Dr. Jana Barinoff barinoff.jana@googlemail.com. Citation Format: Barinoff J, Anastasiadou L, Brandi C, Junker-Stein A, Silbermann J, Langenfeld M, Fortmann C, Thill M. 21-gene recurrence score® in patients with primary metastatic ER+ HER2- breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr OT3-04-04.
Quality of Care at Hospitals Identified as Outliers in Publicly Reported Mortality Statistics for Percutaneous Coronary Intervention
Authors: Stephen W. Waldo, James M. McCabe, Kevin F. Kennedy, Corwin M. Zigler, Duane S. Pinto, Robert W. Yeh
Journal: Circulation (2017)

Public reporting of percutaneous coronary intervention (PCI) outcomes may create disincentives for physicians to provide care for critically ill patients, particularly at institutions with worse clinical outcomes. We thus sought to evaluate the procedural management and in-hospital outcomes of patients treated for acute myocardial infarction before and after a hospital had been publicly identified as a negative outlier.Using state reports, we identified hospitals that were recognized as negative PCI outliers in 2 states (Massachusetts and New York) from 2002 to 2012. State hospitalization files were used to identify all patients with an acute myocardial infarction within these states. Procedural management and in-hospital outcomes were compared among patients treated at outlier hospitals before and after public report of outlier status. Patients at nonoutlier institutions were used to control for temporal trends.Among 86 hospitals, 31 were reported as outliers for excess mortality. Outlier facilities were larger, treating more patients with acute myocardial infarction and performing more PCIs than nonoutlier hospitals (P<0.05 for each). Among 507 672 patients with acute myocardial infarction hospitalized at these institutions, 108 428 (21%) were treated at an outlier hospital after public report. The likelihood of PCI at outlier (relative risk [RR], 1.13; 95% confidence interval [CI], 1.12-1.15) and nonoutlier institutions (RR, 1.13; 95% CI, 1.11-1.14) increased in a similar fashion (interaction P=0.50) after public report of outlier status. The likelihood of in-hospital mortality decreased at outlier institutions (RR, 0.83; 95% CI, 0.81-0.85) after public report, and to a lesser degree at nonoutlier institutions (RR, 0.90; 95% CI, 0.87-0.92; interaction P<0.001). Among patients that underwent PCI, in-hospital mortality decreased at outlier institutions after public recognition of outlier status in comparison with prior (RR, 0.72; 9% CI, 0.66-0.79), a decline that exceeded the reduction at nonoutlier institutions (RR, 0.87; 95% CI, 0.80-0.96; interaction P<0.001).Large hospitals with higher clinical volume are more likely to be designated as negative outliers. The rates of percutaneous revascularization increased similarly at outlier and nonoutlier institutions after report of outlier status. After outlier designation, in-hospital mortality declined at outlier institutions to a greater extent than was observed at nonoutlier facilities.
Cystatin C Level as a Marker of Renal Function in Hematopoietic Stem Cell Transplantation
Authors: Hideharu Muto, Kazuteru Ohashi, Minoru Ando, Ryo Hanajiri, Taku Kikuchi, Wataru Munakata, Chihiro Sakurai, Masahide Yamamoto, Takeshi Kobayashi, Takuya Yamashita, Hideki Akiyama, Hisashi Sakamaki
Journal: Blood (2008)
Increase in outbreaks of gastroenteritis linked to bathing water in Finland in summer 2014
Authors: Ari Kauppinen, Haider Al-Hello, Outi Zacheus, Jaana Kilponen, Leena Maunula, Sari Huusko, Maija Lappalainen, Ilkka Miettinen, Soile Blomqvist, Ruska Rimhanen-Finne
Journal: Eurosurveillance (2017)

An increased number of suspected outbreaks of gastroenteritis linked to bathing water were reported to the Finnish food- and waterborne outbreak (FWO) registry in July and August 2014. The investigation reports were assessed by a national outbreak investigation panel. Eight confirmed outbreaks were identified among the 15 suspected outbreaks linked to bathing water that had been reported to the FWO registry. According to the outbreak investigation reports, 1,453 persons fell ill during these outbreaks. Epidemiological and microbiological data revealed noroviruses as the main causative agents. During the outbreaks, exceptionally warm weather had boosted the use of beaches. Six of eight outbreaks occurred at small lakes; for those, the investigation strongly suggested that the beach users were the source of contamination. In one of those eight outbreaks, an external source of contamination was identified and elevated levels of faecal indicator bacteria (FIB) were noted in water. In the remaining outbreaks, FIB analyses were insufficient to describe the hygienic quality of the water. Restrictions against bathing proved effective in controlling the outbreaks. In spring 2015, the National Institute for Health and Welfare (THL) and the National Supervisory Authority for Welfare and Health (Valvira) published guidelines for outbreak control to prevent bathing water outbreaks.